Seasons Hospice & Palliative Care 5457 Twin Knolls Road, Suite 100, Columbia, MD, 21045 | |
(410) 689-7400 |
News Archive
Osseon® Therapeutics, Inc. announced today that its newest product for vertebral augmentation treatment, the Osseoflex SB (steerable balloon), received CE Mark approval for commercial release in the European Union.
A Rutgers physician who has championed the movement to use less blood in transfusions has been awarded more than $16.1 million by the National Institutes of Health National Heart, Lung, and Blood Institute to lead a nation-wide clinical trial to evaluate whether a restrictive or a liberal blood transfusion is most beneficial to patients who have had a heart attack.
Researchers from the Haematopoietic Differentiation and Stem Cell Biology group at the Centre for Genomic Regulation (CRG), have described one of the mechanisms by which a cell (from the skin, for example) can be converted into another which is completely different.
Testing for some inflammatory proteins associated with the nervous and immune systems will help diagnose the earlier onset and progression of Alzheimer's disease, according to a Rutgers study.
› Verified 1 days ago
Name | Seasons Hospice & Palliative Care |
---|---|
Location | 5457 Twin Knolls Road, Suite 100, Columbia, Maryland |
Hospice ID | 211507 |
Category | Freestanding Hospice |
Ownership Type | Proprietary - Corporation |
Profit Type | FOR PROFIT |
SSA county code | 130 |
News Archive
Osseon® Therapeutics, Inc. announced today that its newest product for vertebral augmentation treatment, the Osseoflex SB (steerable balloon), received CE Mark approval for commercial release in the European Union.
A Rutgers physician who has championed the movement to use less blood in transfusions has been awarded more than $16.1 million by the National Institutes of Health National Heart, Lung, and Blood Institute to lead a nation-wide clinical trial to evaluate whether a restrictive or a liberal blood transfusion is most beneficial to patients who have had a heart attack.
Researchers from the Haematopoietic Differentiation and Stem Cell Biology group at the Centre for Genomic Regulation (CRG), have described one of the mechanisms by which a cell (from the skin, for example) can be converted into another which is completely different.
Testing for some inflammatory proteins associated with the nervous and immune systems will help diagnose the earlier onset and progression of Alzheimer's disease, according to a Rutgers study.
› Verified 1 days ago
NPI Number | 1003813718 |
Organization Name | Seasons Hospice & Palliative Care Of Maryland, Inc |
Address | 5457 Twin Knolls Rd Columbia, Maryland, 21045 |
Phone Number | (888)523-6000 |
News Archive
Osseon® Therapeutics, Inc. announced today that its newest product for vertebral augmentation treatment, the Osseoflex SB (steerable balloon), received CE Mark approval for commercial release in the European Union.
A Rutgers physician who has championed the movement to use less blood in transfusions has been awarded more than $16.1 million by the National Institutes of Health National Heart, Lung, and Blood Institute to lead a nation-wide clinical trial to evaluate whether a restrictive or a liberal blood transfusion is most beneficial to patients who have had a heart attack.
Researchers from the Haematopoietic Differentiation and Stem Cell Biology group at the Centre for Genomic Regulation (CRG), have described one of the mechanisms by which a cell (from the skin, for example) can be converted into another which is completely different.
Testing for some inflammatory proteins associated with the nervous and immune systems will help diagnose the earlier onset and progression of Alzheimer's disease, according to a Rutgers study.
› Verified 1 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 99.9 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 99.7 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 99.6 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 55.9 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 99.8 | 97.3 |
Patients who got timely treatment for shortness of breath | 99.2 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 99.6 | 93.3 |
News Archive
Osseon® Therapeutics, Inc. announced today that its newest product for vertebral augmentation treatment, the Osseoflex SB (steerable balloon), received CE Mark approval for commercial release in the European Union.
A Rutgers physician who has championed the movement to use less blood in transfusions has been awarded more than $16.1 million by the National Institutes of Health National Heart, Lung, and Blood Institute to lead a nation-wide clinical trial to evaluate whether a restrictive or a liberal blood transfusion is most beneficial to patients who have had a heart attack.
Researchers from the Haematopoietic Differentiation and Stem Cell Biology group at the Centre for Genomic Regulation (CRG), have described one of the mechanisms by which a cell (from the skin, for example) can be converted into another which is completely different.
Testing for some inflammatory proteins associated with the nervous and immune systems will help diagnose the earlier onset and progression of Alzheimer's disease, according to a Rutgers study.
› Verified 1 days ago
Home Health Aides | 33 |
Counselors | 5 |
Licensed Practical or Vocational Nurses | 12 |
Medical Social Workers | 10 |
Physicians | 2 |
Registered Nurses | 71 |
Other Personnel | 38 |
Total Employees | 171 |
---|
News Archive
Osseon® Therapeutics, Inc. announced today that its newest product for vertebral augmentation treatment, the Osseoflex SB (steerable balloon), received CE Mark approval for commercial release in the European Union.
A Rutgers physician who has championed the movement to use less blood in transfusions has been awarded more than $16.1 million by the National Institutes of Health National Heart, Lung, and Blood Institute to lead a nation-wide clinical trial to evaluate whether a restrictive or a liberal blood transfusion is most beneficial to patients who have had a heart attack.
Researchers from the Haematopoietic Differentiation and Stem Cell Biology group at the Centre for Genomic Regulation (CRG), have described one of the mechanisms by which a cell (from the skin, for example) can be converted into another which is completely different.
Testing for some inflammatory proteins associated with the nervous and immune systems will help diagnose the earlier onset and progression of Alzheimer's disease, according to a Rutgers study.
› Verified 1 days ago
Others | 83 |
Total Volunteers | 83 |
---|
News Archive
Osseon® Therapeutics, Inc. announced today that its newest product for vertebral augmentation treatment, the Osseoflex SB (steerable balloon), received CE Mark approval for commercial release in the European Union.
A Rutgers physician who has championed the movement to use less blood in transfusions has been awarded more than $16.1 million by the National Institutes of Health National Heart, Lung, and Blood Institute to lead a nation-wide clinical trial to evaluate whether a restrictive or a liberal blood transfusion is most beneficial to patients who have had a heart attack.
Researchers from the Haematopoietic Differentiation and Stem Cell Biology group at the Centre for Genomic Regulation (CRG), have described one of the mechanisms by which a cell (from the skin, for example) can be converted into another which is completely different.
Testing for some inflammatory proteins associated with the nervous and immune systems will help diagnose the earlier onset and progression of Alzheimer's disease, according to a Rutgers study.
› Verified 1 days ago
Seasons Hospice & Palliative Care Location: 5457 Twin Knolls Road, Suite 100, Columbia, Maryland, 21045 Phone: (410) 689-7400 |